Cargando…

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Philip R., Kato, Shumei, Goodman, Aaron M., Ikeda, Sadakatsu, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578053/
https://www.ncbi.nlm.nih.gov/pubmed/28788102
http://dx.doi.org/10.3390/ijms18081663
_version_ 1783260457842245632
author Cohen, Philip R.
Kato, Shumei
Goodman, Aaron M.
Ikeda, Sadakatsu
Kurzrock, Razelle
author_facet Cohen, Philip R.
Kato, Shumei
Goodman, Aaron M.
Ikeda, Sadakatsu
Kurzrock, Razelle
author_sort Cohen, Philip R.
collection PubMed
description Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generation sequencing of his metastatic liver tumor demonstrated a high tumor mutational burden (103 mutations per megabase) and the genomic amplification of PD-L1, both of which are features that predict response to anti-PD1/PD-L1 immunotherapy. Treatment with nivolumab, an anti-PD1 checkpoint inhibitor, resulted in near complete remission. Yet, he developed new primary cutaneous basal cell carcinomas while receiving immunotherapy and while his metastatic disease showed an ongoing response. His new superficial skin cancer had a lower tumor mutational burden (45 mutations per megabase) than the metastatic disease. Since immunotherapy response rates are higher in patients with more genomically complex tumors, our observations suggest that, in contrast with the premise of earlier treatment is better, which holds true for targeted and cytotoxic therapies, immunotherapy may be better suited to more advanced disease.
format Online
Article
Text
id pubmed-5578053
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55780532017-09-05 Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease Cohen, Philip R. Kato, Shumei Goodman, Aaron M. Ikeda, Sadakatsu Kurzrock, Razelle Int J Mol Sci Case Report Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generation sequencing of his metastatic liver tumor demonstrated a high tumor mutational burden (103 mutations per megabase) and the genomic amplification of PD-L1, both of which are features that predict response to anti-PD1/PD-L1 immunotherapy. Treatment with nivolumab, an anti-PD1 checkpoint inhibitor, resulted in near complete remission. Yet, he developed new primary cutaneous basal cell carcinomas while receiving immunotherapy and while his metastatic disease showed an ongoing response. His new superficial skin cancer had a lower tumor mutational burden (45 mutations per megabase) than the metastatic disease. Since immunotherapy response rates are higher in patients with more genomically complex tumors, our observations suggest that, in contrast with the premise of earlier treatment is better, which holds true for targeted and cytotoxic therapies, immunotherapy may be better suited to more advanced disease. MDPI 2017-07-31 /pmc/articles/PMC5578053/ /pubmed/28788102 http://dx.doi.org/10.3390/ijms18081663 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Cohen, Philip R.
Kato, Shumei
Goodman, Aaron M.
Ikeda, Sadakatsu
Kurzrock, Razelle
Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title_full Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title_fullStr Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title_full_unstemmed Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title_short Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
title_sort appearance of new cutaneous superficial basal cell carcinomas during successful nivolumab treatment of refractory metastatic disease: implications for immunotherapy in early versus late disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578053/
https://www.ncbi.nlm.nih.gov/pubmed/28788102
http://dx.doi.org/10.3390/ijms18081663
work_keys_str_mv AT cohenphilipr appearanceofnewcutaneoussuperficialbasalcellcarcinomasduringsuccessfulnivolumabtreatmentofrefractorymetastaticdiseaseimplicationsforimmunotherapyinearlyversuslatedisease
AT katoshumei appearanceofnewcutaneoussuperficialbasalcellcarcinomasduringsuccessfulnivolumabtreatmentofrefractorymetastaticdiseaseimplicationsforimmunotherapyinearlyversuslatedisease
AT goodmanaaronm appearanceofnewcutaneoussuperficialbasalcellcarcinomasduringsuccessfulnivolumabtreatmentofrefractorymetastaticdiseaseimplicationsforimmunotherapyinearlyversuslatedisease
AT ikedasadakatsu appearanceofnewcutaneoussuperficialbasalcellcarcinomasduringsuccessfulnivolumabtreatmentofrefractorymetastaticdiseaseimplicationsforimmunotherapyinearlyversuslatedisease
AT kurzrockrazelle appearanceofnewcutaneoussuperficialbasalcellcarcinomasduringsuccessfulnivolumabtreatmentofrefractorymetastaticdiseaseimplicationsforimmunotherapyinearlyversuslatedisease